Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The cardiovascular morbidity in developed countries has decreased, but only in men and it has increased in women. The risk of cardiovascular diseases in premenopausal women is 2-4 times less than this in men. A role of hormone replacement therapy for postmenopausal women in primary and secondary prevention of cardiovascular diseases is reviewed. The results of retrospective and plaсebo-controlled trials are presented. Cellular cardioprotective mechanisms of action of female sex hormones are shown.

About the Authors

S. N. Tereshchenko
Moscow State Medical Stomatological University
Russian Federation

I. V. Zhirov
Moscow State Medical Stomatological University
Russian Federation

E. S. Krasilnikova
Moscow State Medical Stomatological University
Russian Federation

E. E. Kazantseva
Moscow State Medical Stomatological University
Russian Federation


1. Баранова Е.И, Большакова О.О., Маслова Н.П. и др. Опыт применения нолипрела и его сочетания с заместительной гормональной терапией у женщин с гипертонической болезнью в постменопаузе. Артериальная гипертензия 2005;(1):24-7.

2. Бритов А.Н., Быстрова М.М. Заместительная гормональная терапия в профилактике сердечно-сосудистых заболеваний у женщин с артериальной гипертонией и ишемической болезнью сердца. Consilium medicum 2002; 7(экстравыпуск):10-5.

3. Вебер В.Р. Артериальная гипертензия у женщин в постменопаузальном периоде. Сердце 2006;(7):346-52.

4. Катхурия Ю.Б., Калашникова М.Ф., Мельниченко Г.А. Особенности заместительной гормональной терапии у женщин с эндокринными заболеваниями. Гинекология 2002;1(1):34-41.

5. Остроумова О.Д. Заместительная гормональная терапия в постменопаузе для вторичной профилактики ишемической болезни сердца: точка или многоточие? Сonsilium medicum 2002;(экстравыпуск):11-4.

6. Сметник В.П. Защитное влияние эстрогенов на сердечно-сосудистую систему. Consilium medicum 2002;(экстравыпуск):3-6.

7. Barrett-Connor E. Hormone replacement therapy. BMJ 2004;4(3):457-67.

8. Baler L., Meldrum K., Wang M. et al. The role of estrogen in cardiovascular disease. J Surg Res. 2003;115(2):325-44.

9. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53(3):672-7.

10. Genazzani AR. Controversial issues in climacteric medicine (I) Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK. Maturitas. 2001;38(3):263-71.

11. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-75.

12. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997;315:149-53.

13. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-45.

14. Hulley S., Grady D., Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13.

15. Lawlor DA, Ebrahim S, Davey Smith G. Role of endogenous oestrogen in etiology of coronary heart disease: analysis of age related trends in coronary heart disease and breast cancer in England, Wales and Japan. BMJ. 2002;325(7359):311-2.

16. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart fаilure. J Am Coll Cardiol. 2003;42(7):1238-45.

17. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-34.

18. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321(10):641-6.

19. Minelli C, Abrams K.R., Sutton A.J. et al. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ. 2004;328:371.

20. Løkkegaard E, Pedersen AT, Heitmann BL, et al. Relation between hormone replacement therapy and ischemic heart disease in women: prospective observation study. BMJ. 2003;326:426.

21. Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-9.

22. Rymer J., Wilson R., Ballard K. Making decisions about hormone replacement therapy. BMJ. 2003;326:322-6.

23. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335:239.

24. Wenger N. Coronary heart disease: an older woman’s major health risk. BMJ. 1997;315(7115):1085-90.

25. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199-208.

For citation:

Tereshchenko S.N., Zhirov I.V., Krasilnikova E.S., Kazantseva E.E. FEMALE SEX HORMONES AS MODULATORS OF GENDER DIFFERENCES IN RESPONSE TO PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2007;3(5):83-87. (In Russ.)

Views: 1507

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)